Axplora in the news

Axplora is developing Axotecan to establish an independent European source of Exatecan for ADC developers, with GMP supply targeted for late 2027.

Axplora is enhancing cleanroom energy efficiency and exploring renewable technologies to meet ambitious emissions reduction targets driven by customer expectations and sustainability commitments.

Axplora Group's global employee count grew to 1,596 by March 2026, a 1.9% increase since 2023.

Axplora is consolidating ursodeoxycholic acid manufacturing at its Vizag, India, site, transitioning production from Italy to leverage green chemistry and an FDA-approved facility for enhanced operational efficiency and customer value.

Axplora is shifting all ursodeoxycholic acid (UDCA) manufacturing to its Vizag, India site from Italy by 2026, to enhance production capacity and leverage business unit strengths.

Axplora is consolidating all UDCA manufacturing at its Vizag, India, facility by 2026, leveraging green chemistry and integrated operations.

Arsalan Khan, a former engineer, now leads marketing strategy at Axplora, applying his technical knowledge to bold campaigns like "Dare to Imagine" within the CDMO sector.

Axplora's leaders explain how an agile partnership approach helps biopharma companies navigate complexity and accelerate drug development and delivery.

Axplora is investing $60 million to expand its highly potent active pharmaceutical ingredient production capabilities in Italy, aiming to accelerate drug development and commercialization.

Axplora is building a new facility as part of a $60 million investment to expand its highly potent active pharmaceutical ingredient manufacturing capabilities and integrate R&D, quality control, and production.

Axplora is investing over …100 million in its global manufacturing network to expand highly potent active pharmaceutical ingredient capabilities and enhance supply chain resilience and sustainability.

David Gonzalez has been appointed President Commercial – Specialty Products Business Unit at Axplora to lead commercial strategy, global sales, market expansion, and customer partnerships.

Axplora invests $60 million to expand its Italian API manufacturing plant, enhancing R&D and high-potency API production.

Axplora invests $60 million to expand its Italian Farmabios site with a new R&D and laboratory hub for highly potent active pharmaceutical ingredient manufacturing.

Axplora is investing $60 million to expand its HPAPI manufacturing facility in Italy to meet growing demand for high-potency molecules and accelerate drug development for its customers.

Axplora is investing $60 million to expand its highly potent API manufacturing and R&D capabilities at its Farmabios site, targeting completion by February 2027.

Axplora is expanding its Le Mans manufacturing site with new lyophilization capacity by 2027 to meet increased demand for antibody-drug conjugates.

The article describes Axplora's historical Schlebusch plant, originally Dynamit Nobel, highlighting its past in explosives manufacturing and current role as a contract manufacturer for pharmaceutical APIs and specialty chemicals.

Axplora opens a cGMP pilot plant in Leverkusen for flow chemistry, aiming to enhance pharmaceutical production through continuous processing.

Axplora opened a cGMP pilot plant for flow chemistry in Leverkusen to enhance efficient and sustainable production of complex APIs.